Literature DB >> 15138682

[The Explanatory Model-Interview in the diagnosis of orthopaedic pain patients].

C Schröter1, M Schiltenwolf, T Fydrich, P Henningsen.   

Abstract

AIM: This study aims to clarify weather the Explanatory Model Interview (EMIC, Weiss, 1997) can detect differences between pain patients with somatoform disorders and pain patients without any psychiatric disorder. We consider the importance of psychological symptom reporting, somatic illness attribution and the subjective experience of exhaustion.
METHODS: The (EMIC) and the Structured Clinical Interview for DSM-IV (SKID) were administered to 87 in-patients recruited from the pain therapy ward of the Orthopaedic Clinic in Heidelberg, Germany. The analysis of the EMIC strongly reflects interactional factors and the subjective importance for the patients.
RESULTS: Patients with somatoform disorders reported more psychological distress than patients without psychiatric disorder, especially after inquiry. Physical exhaustion was clearly more important in the symptom attribution of somatic pain patients, but an exclusive somatic illness attribution did not appear more often in this group of patients.
CONCLUSIONS: Most pain patients with somatoform disorders report psychological distress when they are encouraged. In spite of this emotional strain, most of the pain patients with somatoform disorders attribute their pain complaints to somatic causes. The conspicuous importance of exhaustion in the attribution of patients with somatoform disorders confirms clinical observations and requires further research.

Entities:  

Mesh:

Year:  2004        PMID: 15138682     DOI: 10.1007/s00132-003-0612-1

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  8 in total

1.  Medically unexplained symptoms: how often and why are they missed?

Authors:  C Nimnuan; M Hotopf; S Wessely
Journal:  QJM       Date:  2000-01

2.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

3.  Iatrogenic factors and chronic pain.

Authors:  K Kouyanou; C E Pither; S Wessely
Journal:  Psychosom Med       Date:  1997 Nov-Dec       Impact factor: 4.312

4.  The temporal stability and co-morbidity of prolonged fatigue: a longitudinal study in primary care.

Authors:  I Hickie; A Koschera; D Hadzi-Pavlovic; B Bennett; A Lloyd
Journal:  Psychol Med       Date:  1999-07       Impact factor: 7.723

5.  The interrelationship of tropical disease and mental disorder: conceptual framework and literature review (Part I--Malaria).

Authors:  M G Weiss
Journal:  Cult Med Psychiatry       Date:  1985-06

6.  Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study.

Authors:  G E Simon; M VonKorff
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

7.  Psychiatric illness in patients with persistent somatisation.

Authors:  P Fink
Journal:  Br J Psychiatry       Date:  1995-01       Impact factor: 9.319

Review 8.  Symptom attribution in cultural perspective.

Authors:  L J Kirmayer; A Young; J M Robbins
Journal:  Can J Psychiatry       Date:  1994-12       Impact factor: 4.356

  8 in total
  4 in total

1.  [Somatoform pain disturbance as the result of trauma].

Authors:  N Schmelzer-Schmied; P Henningsen; M Schiltenwolf
Journal:  Orthopade       Date:  2006-12       Impact factor: 1.087

2.  Differences and similarities in explanatory models of hypertension in the United States of america, Tanzania and Jamaica.

Authors:  J D Purakal; J Williams-Johnson; E W Williams; S Pemba; J Kambona; R Welch; J Flack; P Levy
Journal:  West Indian Med J       Date:  2014-06-11       Impact factor: 0.171

3.  [Chronic knee pain and specific heat phobia. A case report].

Authors:  W Pepke; E Neubauer; M Schiltenwolf
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

4.  [Assessment of musculoskeletal pain].

Authors:  M Schiltenwolf
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.